Skip to Content

JavaScript has been disabled within your browser, the content or the functionality of this web page can be limited or unavailable.

There is no panel matching the key "Alert---Site-Wide"

Clinical Trials Search Results

Search for

in

Accepting Participants (9)

Showing 1-9 of 9

Sorted By:

A-Z
Z-A

Previous Next

(NSABP B-64) EXActDNA-003: Breast Cancer Clinical Validation Study to Predict Recurrence of High-Risk Early Breast Cancer Treated with Neoadjuvant Therapy Using a Bespoke Circulating Tumor DNA Assay to Detect Molecular Residual Disease
participants planning to undergo chemo for high-risk, early breast cancer, who are willing to provide tissue and blood specimens for circulating tumor DNA (ctDNA) analysis
A092205_HNSCC: Randomized Phase III Trial of Pembrolizumab vs. Pembrolizumab/Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Platinum Refractory Disease
PhIII Trial of Pembro vs Pembro/Cetux in Recurrent or Metastatic HN Squamous Cell Carcinoma with Platinum Refractory Disease
ALLO-501A-202: A Randomized, Open-Label Study Evaluating the Efficacy and Safety of Cemacabtagene Ansegedleucel in Participants with Minimal Residual Disease after Response to First Line Therapy for Large B-Cell Lymphoma (ALPHA3)
ALLO-501A-202 Randomized, Open-Label Study Evaluating Efficacy and Safety Cemacabtagene Ansegedleucel for Large B-Cell Lymphoma (ALPHA3)
CAMBRIA-1: A Phase III Open-Label Randomised Study to Assess Efficacy & Safety of Extended Therapy with Camizestrant (AZD9833, Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in ER+/HER2- Early Breast Cancer & Intermediate or High Risk of Recurrence Who Have Completed Definitive Locoregional Therapy and at Least 2 Years Standard Adjuvant Endocrine-Based Therapy Without Disease Recurrence (enrollment paused 11-Apr-2025)
camizestrant vs ET in patients w/ ER+/HER2- early BC w/ risk for disease recurrence who completed treatment & adjuvant ET for 2-5 years. Duration of treatment is 60 months
GCT 1046-06: A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06)
acasunlimab in combo with pembro vs docetaxel in participants with PD-L1-positive metastatic NSCLC have been treated PD-1)/PD-L1 inhibitor, platinumcontaining chemo
NRG-BR009: A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients with pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score
A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemo to Ovarian Function Suppression + Endo Therapy in premenopausal pts w/pN0-1 ER-Positive/HER2-Negative
NRG-GU008: Randomized Phase III Trial Incorporating Apalutamide and Advanced Imaging into Salvage Treatment for Patients with Node-Positive Prostate Cancer after Radical Prostatectomy (INNOVATE*) *INtensifying treatment for NOde positive prostate cancer by VArying the hormonal ThErapy
NRG-GU008, Phase III Trial Incorporating Apalutamide & Advanced Imaging into Salvage Treatment for Pts w/ Node-Positive Prostate Ca after Radical Prostatectomy (INNOVATE*)
NRG-GY036: A PHASE III TRIAL OF ONE VS. TWO YEARS OF MAINTENANCE OLAPARIB, WITH OR WITHOUT BEVACIZUMAB, IN PATIENTS WITH BRCA1/2 MUTATED OR HOMOLOGOUS RECOMBINATION DEFICIENT (HRD+) OVARIAN CANCER FOLLOWING RESPONSE TO FIRST LINE PLATINUM-BASED CHEMOTHERAPY
phase III trial compares olaparib for one year vs two years, with or without bevacizumab in BRCA 1/2 mutated or HRD+ stage III or IV ovarian cancer
SWOG S2209: A Phase III Randomized Trial for Newly Diagnosed Multiple Myeloma (NDMM) Patients Considered Frail or in a Subset of "Intermediate Fit" Comparing Upfront Three-Drug Induction Regimens Followed by Double or Single-Agent Maintenance
Ph. III Rand. Trial for New Diagnosed Multiple Myeloma Pts Considered Frail/Subset of "Interm. Fit" Comparing Upfront 3-Drug Induct. Regimens Followed by Dbl/Sing-Agent Maint.

Previous Next